Specialty funds cover your exercise cost. Zero personal liability if the company fails.
Specialized private credit funds advance the capital necessary to cover both the aggregate strike price and the estimated tax liabilities. The defining characteristic is the collateral structure: the loan is secured exclusively by the shares being purchased. No personal assets (homes, savings, future wages) are at risk. The loan does not require interim monthly payments; interest and fees accrue and compound, remaining entirely outstanding until the final IPO or acquisition settlement date. If the company achieves a successful exit, the borrower repays principal, accrued interest, and a predetermined carry percentage out of the proceeds. If the company fails, the lender absorbs the total financial loss.
Non-recourse financing has three economic components that collectively consume 20–50% of the final share value. First, an origination fee of 2–6% of the advanced amount, almost never paid upfront: it's capitalized into the initial loan balance. Second, an accruing interest rate of 7–12% annually that compounds over the full life of the loan until the exit event. Third, an upside participation (carry) fee of 5–30% of the terminal equity value, assessed against the gains realized at sale. Because the lender assumes all downside risk in a highly speculative asset class, this cost structure is how they price that risk.
Non-recourse providers deploy rigorous underwriting standards. They exclusively finance employees at late-stage, highly vetted companies (established unicorns) with a high statistical probability of a near-term successful exit. They diversify their fund's risk across a portfolio of premium startups. This means not everyone can access non-recourse financing; it's primarily available to employees at well-known, high-valuation private companies where the lender has high conviction. The availability of non-recourse financing has dismantled the 'golden handcuffs' paradigm: employees can now exercise and leave without risking personal financial ruin, restoring labor mobility.
The lender absorbs the total loss. Your personal assets (home, savings, future income) are entirely insulated. You lose the equity value (which would be zero anyway) and the upside you would have had, but you owe nothing further. This is the fundamental distinction from recourse financing.
At exit: (1) calculate total equity value (shares × IPO price); (2) subtract the compounded loan balance (principal × (1 + rate)^years); (3) subtract the carry fee (carry % × amount above the compounded balance). What remains is your net proceeds. If equity value is less than the compounded loan balance, you owe nothing. The lender takes the equity and absorbs the shortfall.
No, the AMT calculation is based on the spread at exercise regardless of how you funded the exercise. Non-recourse financing covers your upfront cash outlay (strike + tax), including the AMT payment itself. So it solves the 'I can't afford to exercise' problem, but the AMT event still occurs in the year you exercise.
These providers operate in the Non-Recourse Financing space. StrikeRates does not endorse or recommend any provider. Review each independently.
Use the scenario modeler to see how Non-Recourse Financing mechanics play out with your specific grant, or join the waitlist for deeper, personalized equity intelligence.